CKDXF (Ceryvyn Therapeutics) Total Stockholders Equity: $-201.07 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Ceryvyn Therapeutics Total Stockholders Equity?

Ceryvyn Therapeutics CKDXF Total Stockholders Equity is $-201.07 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

Ceryvyn Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2025 was $-201.07 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Ceryvyn Therapeutics's Book Value per Share for the quarter that ended in Jun. 2025 was $-0.16. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Ceryvyn Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2025 was 0.00.

Ceryvyn Therapeutics  (OTCPK:CKDXF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Ceryvyn Therapeutics's Book Value per Share for the quarter that ended in Jun. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-201.069-0)/1231.817
=-0.16

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Ceryvyn Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -201.069
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Total Stockholders Equity Related Terms

Ceryvyn Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Total Stockholders Equity Chart

Ceryvyn Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 135.29 47.98 -5.85 -75.81 -201.07

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.85 -46.91 -75.81 -168.71 -201.07
What does a Total Stockholders Equity of $-201.07 Mil mean?
Ceryvyn Therapeutics (CKDXF) has a Total Stockholders Equity of $-201.07 Mil as of Jun. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics' Total Stockholders Equity too high?
Ceryvyn Therapeutics' current Total Stockholders Equity is $-201.07 Mil.
How does Ceryvyn Therapeutics' Total Stockholders Equity compare to VRTX and REGN?
Ceryvyn Therapeutics' Total Stockholders Equity of $-201.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current Total Stockholders Equity is $-201.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (CKDXF) has a current Total Stockholders Equity of $-201.07 Mil. The current Total Stockholders Equity is $-201.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Ceryvyn Therapeutics (CKDXF), the current Total Stockholders Equity is $-201.07 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.